Johnson & Johnson (JNJ) fundamentals: P/E, valuation, undervalued?
Johnson & Johnson · Health Care · ref. ETF XLV · price $265.77
In short — Johnson & Johnson trades at 30.9× earnings (P/E), 21.6× forward, with a net margin of 21.5 % and revenue growth of +7 %. Read: High P/E (P/E 31 (above average)).
Is Johnson & Johnson stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$265.77+51.5% over range
Aug 28, 25low $174.16 · high $273.41Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
69% recommend buying · 13 analysts
Valuation : High P/E — P/E 31 (above average)
Valuation
30.9
P/E (price/earnings)
21.6
Forward P/E
—
PEG
7.5
Price/book (P/B)
$640.5B
Market cap
8.61
EPS
Profitability & growth
21.5 %
Net margin
+7 %
Revenue growth
-1 %
Earnings growth
$49.0B
Total debt
Johnson & Johnson income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $94.9B | $17.9B | 18.9 % |
| 2023 | $85.2B | $35.2B | 41.3 % |
| 2024 | $88.8B | $14.1B | 15.8 % |
| 2025 | $94.2B | $26.8B | 28.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Johnson & Johnson's P/E and is the stock undervalued? What's a good P/E?
Johnson & Johnson's P/E is 30.9 (forward 21.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Johnson & Johnson profitable?
Johnson & Johnson has a net margin of 21.5 % (EPS 8.61). The company is profitable.
Is JNJ stock expensive?
Our read: "High P/E" — P/E 31 (above average). Cross-check with growth and sector.
💬 A question about Johnson & Johnson? The JPI assistant answers using our backtest data.
Keep exploring Johnson & Johnson